NAFDAC alerts public on sale of fake TANDAK injection in Nigeria

93

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public warning against the sale of counterfeit TANDAK injectable 1.5g powder and water for injection, which is made by Intracin Pharmaceuticals PVT. LTD in Gujarat, India.

Marcson Healthcare Ltd., the Marketing Authorization Holder (MAH), notified the FDA about the discovery of this substance in Gombe state, Nigeria.

TANDAK® injection of 1.5g powder is an important co-formulation of Ceftriaxone 1000mg and Sulbactam 500mg used to treat a variety of bacterial illnesses. Its effectiveness is dependent on the supervision of healthcare professionals, who ensure proper administration and monitoring.

According to NAFDAC, the illegal circulation of counterfeit medicines poses significant health risks to consumers, as these products do not adhere to regulatory standards, compromising safety, quality, and efficacy. 

In response to this discovery, NAFDAC has instructed all zonal directors and state coordinators to conduct surveillance and eliminate counterfeit products from their respective zones and states. 

Importers, distributors, retailers, healthcare professionals, and caregivers are urged to exercise caution and vigilance within the supply chain to prevent the importation, distribution, sale, and use of counterfeit products.  

They are reminded to source medical products exclusively from authorized and licensed suppliers, ensuring thorough inspection of authenticity and physical condition. 

Furthermore, healthcare professionals and consumers are encouraged to report any suspicions of substandard or falsified medicines or medical devices to the nearest NAFDAC office, or through designated communication channels such as NAFDAC’s hotline and email address. 

Additionally, healthcare professionals and patients are advised to report any adverse events or side effects associated with the use of medicinal products or devices to NAFDAC, utilizing available reporting platforms on the agency’s website or through the Med-safety application on Android and IOS stores.